Daiichi Sankyo Submits WelChol sNDA For Diabetes Indication
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo is seeking an expanded indication for its LDL-cholesterol lowering agent WelChol (colesevelam HCI) to improve glycemic control in patients with type 2 diabetes. If approved, the drug would be the first LDL lowering medication also indicated for improving glycemic control.